Health Condition 1: null- Stable Chronic Bronchitis
Conditions
Interventions
Intervention1: Vasavleha: Vasavleha
Dose :10gm twice daily
Dosage Form: Avaleha
Route of Administration: Oral
Time of Administration:Twice a day after food
Anupana: Water
Packing Form:300gm jar
Durati
Sponsors
Central Council for Research in Ayurvedic Sciences
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patients of either sex aged between 16 to 70 years. 2. Patient with history of uncomplicated Chronic Bronchitis (Chronic Bronchitis is defined as a cough that occurs every day with sputum production that lasts for at least three months, two years in a row). 3. Patient willing and able to participate in the study for 14weeks
Exclusion criteria
Exclusion criteria: 1. Patients suffering from Acute Bronchitis. 2. Patients having PEFR 3. Other pulmonary diseases like Emphysema, Cor pulmonale, Cyanosis, Pneumonia, Asthma, Cystic fibrosis, Tuberculosis, Lung cancer etc. 4. Patients with uncontrolled Diabetes Mellitus (Blood Sugar Fasting > 250mg/dl) 5. Patients with poorly controlled Hypertension ( >160/100mm of Hg) 6.Patients on prolonged ( > 6 weeks) medication with corticosteroids,bronchodilators, mast cell stabilizers, anti-depressants, anticholinergics, etc. or any other drugs that may have an influence on the outcome of the study. 7. Patients suffering from major systemic illness necessitating long term drug treatment (Rheumatoid arthritis, Tuberculosis, Psycho-Neuro - Endocrinal disorders, etc.) 8. Patients who have a past history of Atrial Fibrillation, Acute Coronary Syndrome, Myocardial Infarction, Stroke or Severe Arrhythmia in the last 6 months. 9. Symptomatic patients with clinical evidence of Heart failure. 10. Patients with concurrent serious hepatic disorders (defined as Aspartate Amino Transferase (AST) and / or Alanine Amino Transferase (ALT), Total Bilirubin, Alkaline Phosphatase (ALP) > 2 times upper normal limit) or Renal Disorders (defined as S. Creatinine >1.2mg/dL). 11. Alcoholics and/or drug abusers. 12. H/o hypersensitivity to the trial drug or any of its ingredients. 13. Patients who have completed participation in any other clinical trial during the past six (06) months. 14. Pregnant or lactating women 15. Any other condition which the Investigator thinks may jeopardize the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in clinical symptoms of chronic bronchitis.Timepoint: 14th day, 28th day, 42nd day, 56th day, 70th day and 84th day and after 2 weeks of follow up study. | — |
Secondary
| Measure | Time frame |
|---|---|
| Change in St. Georgeâ??s Respiratory Questionnaire (SGRQ) scores Any acute exacerbations of Bronchitis occuring during the trial period. Timepoint: 14th day, 28th day, 42nd day, 56th day, 70th day and 84th day and after 2 weeks of follow up study | — |
Countries
India
Contacts
Public ContactDr Subhash singh
M.S. Ayurveda Central Research Institute
Outcome results
None listed